What was the outcome of the VA-HIT trial?
The VA-HIT trial found evidence that gemfibrozil reduces risk of major cardiovascular events (i.e., fatal CHD, nonfatal MI, and stroke) by 42% compared with placebo (RR 0.58; 95% CI 0.38 0.89) in a post hoc analysis.